wjpmr, 2025, 11(7), 21-25

SJIF Impact Factor: 6.842

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Review Article

ISSN 2455-3301

WJPMR

A REVIEW ON PEPTIC ULCER DISEASE

Priya[1*] and Bhavya Gupta

Assistant Professor School of Pharmacy, Maya Devi University, Dehradun.

***Corresponding Author: Priya**

Assistant Professor School of Pharmacy, Maya Devi University, Dehradun.

Article Received on 25/04/2025 **Article Revised on 13/05/2025** **Article Accepted on 03/06/2025**

ABSTRACT

Peptic ulcer can be delineated as the presence of a deep destruction of the mucosa of the stomach and/or duodenum, reaching beyond the muscularismucosa, specifically to the muscle subcaste owing to the environmental gastric acid conflation. Peptic ulcer, also known as stomach ulcer, is a breakage of mucosal filing of stomach, first section of the small intestine and occasionally in the lower oesophagus. Caffeine and coffee are nowhere considered to precedent or exaggerate pains, appear to have lower consequence. Goals of operation are to relieve ulcer pain, heal the ulcer, avert ulcer rush, minimize ulcer-related complications, and eradicate Helicobacter-pylori in Helicobacter-pylori- positive cases.

KEYWORDS: Peptic ulcer disease; Helicobacter pylori infection, Pathophysiology, Symptoms, Types, Treatment.

INTRODUCTION

Peptic ulcer can be delineated as the presence of a deep destruction of the stomach lining or mucosa and/or duodenum, reaching beyond the muscularis mucosa, specifically to the muscle subs caste owing to the environmental gastric acid conflation. The two consummate ubiquitous etiological precedents are the habitual infection with Helicobacter-pylori (Hp) and the use of NSAIDs, involving of course, the ASA. There are distinctive lower ubiquitous precedents that can beget a PU, which are thought-out together, responsible for < 5% of cases. Zollinger-Ellison syndrome (ZES) or gastronomy is one amid them which is a neuroendocrine tumour, frequently located at the head of the pancreas or in the duodenal wall, hyperactive and gastrin secretory.[1] Ageing is claimed to escalate the pitfall for several gastroduodenal diseases, like as gastric atrophy with intestinal metaplasia, PUD, ulcer bleeding and gastric cancer.[2] The unknown cause peptic ulcer diseases are delineated as a painful sore that is not well-known precedent or a painful sore seems to arise spontaneously. Peptic ulcers are acid-initiated lesions rebounded in the stomach & duodenum described by peeled mucosa with the failing dragging into the submucosa or muscularis propria. Lesions that do not reach this depth are called attritions.[3] Gastric acid is well characterized as the precedent of peptic ulcer, while H. pylori infection is honoured as the major causative factor in ulcer conformation. The bacterium precedents amp in the stashing of gastric acid owing to gastritis, and this cycle attributes to corrosion of the mucosa and ulcer conformation. Likewise, imbalance between obnoxious factors (inordinate gastric acid, H. pylori, gallbladder fluid, and elevated free revolutionaries) and protective factors (mucosa, blood fluid, prostaglandins, and antioxidants) perhaps also result in development peptic ulcer**.** Traditionally, mucosal dislocation in cases with the acid peptic complaints is considered to be a result of a hypersecretory acidic terrain together with salutary factors or stress. Threat factors for developing peptic ulcer include H. pylori infection, alcohol and tobacco consumption, non-steroidal anti-inflammatory drugs (NSAIDs) use, and Zollinger–Ellison syndrome.[4] The main threat factors for both gastric and duodenal ulcers are H. pylori infection and NSAID use.[5] NSAIDs develop peptic ulcer complaint, meaning that individual vulnerability is important in the beginning of mucosa damage. Functional polymorphisms in different cytokine genes are associated with peptic ulcers. For illustration, polymorphisms of interleukin 1 beta (IL1B) affect mucosal interleukin 1β product, causing H. pylori-associated gastroduodenal conditions.[6]

Pathogenesis of Peptic Ulcer

Nearly half of the world's population is settled by H. pylori, which remains one of the most common causes of peptic ulcer complaint.[7] The frequence of H. pylori is advanced in developing countries, especially in Africa, Central America, Central Asia, and Eastern Europe.[8] The organism is generally acquired in nonwage in an terrain of unsanitary conditions and crowding, sustainably in countries with lower socioeconomic status. H. pylori cause epithelial cell degeneration and injury, which is generally more severe in the antrum, by the

seditious response with neutrophils, lymphocytes, plasma cells, and macrophages. The medium by which H. pylori induce the development of different types of lesions in the gastroduodenal mucosaisnotfully explained. Pylori infection careful tine ither hypochlorhydria or hyperchlorhydria, therefore determining the type of peptic ulcer. The main intercessors of Pylori infection are cytokines that inhibit parietal cell stashing, but H. pylori can directly affect the H+/K+ ATPase α-subunit, spark calcitonin gene-related peptide (CGRP) sensitive neurons linked to somatostatin, or inhibit the production of gastrin.[9] Although the conformation of gastric ulcers is associated with hypo stashing, 10–15% of cases with H. pylori infection have increased gastric stashing caused by hypergastrinemia and reduced antral somatostatin content.[10] This leads to increased histamine stashing, and subsequently the increased stashing of acid or pepsin from parietal and gastric cells. Also, the eradication of H. pylori leads to a drop in gastrin mRNA expression and an increase in somatostatin mRNA expression.[11] In the remaining majority of cases, gastric ulcers are associated with hypochlorhydria and mucosal atrophy. The main medium of NSAID-associated damage of the gastroduodenal mucosa is the systemic inhibition of constitutively expressed cyclooxygenase-1 (COX-1), which is responsible for prostaglandin conflation, and is associated with dropped mucosal blood flow, low mucus and bicarbonate stashing, and the inhibition of cell proliferation. NSAIDs inhibit the enzyme reversibly in a attention-dependent manner. The co-administration of exogenous prostaglandins and cyclooxygenase-2 (COX-2)-picky NSAIDs use reduces mucosal damage and the threat of ulcers.[12] still, the different physicochemical parcels of NSAIDs cause differences in their toxicity.[20] NSAIDs disrupt mucus phospholipids and lead to the uncoupling of mitochondrial oxidative phosphorylation, therefore initiating mucosal damage. When exposed to acidic gastric juice (pH 2), NSAIDs become protonated and cross lipid membranes to enter epithelial cells (pH 7.4), where they ionize and release H+. In that form, NSAIDs cannot cross the lipid membrane, and are trapped in epithelial cells, leading to the uncoupling of oxidative phosphorylation, dropped mitochondrial energy product, increased cellular permeability, and reduced cellular integrity. Cases who have a history of peptic ulcers or hemorrhage, are over the age of 65, also use steroids or anticoagulants, and take high boluses or combinations of NSAIDs are at the loftiest threat for acquiring NSAID-convinced ulcers.[1]



Pathophysiology

Under normal conditions, duodenal and gastric mucosa integrity is maintained by the mucus-bicarbonate barrier, the neutral pH, and nonstop epithelial cell renewal.[13,25] PGE2 amp cell proliferation, mucus, and H3CO3 stashing, promoting an essential work in mucosa preservation. Distinctive pivotal factor in gastric homeostasis is sufficient blood flow. The NO and PGs Ubiquitous pitfall factors precedents for PUD and gastritis involve infection with Helicobacter pylori, and NSAIDs. Lower ubiquitous pitfall factors involve alcohol, smoking, cocaine, severe illness, autoimmune problems, and radiation remedy and Crohn disease amid distinctive.[16]

Helicobacter pylori: The mechanisms, through which the Hp favours the advancement of PU, are more known in the duodenal, than in gastric side.[17] H. pylori precedent an seditious responses with neutrophils, lymphocytes, plasma cells, and macrophages within the mucosal subcaste and precedent's epithelial cell degeneration and damage. Gastritis is frequently further severe in the antrum, with little or no inflammation in the corpus. Entire cases resulted to have peptic ulcers should be tested for H. pylori.[18] Inflammation consorted with H pylori infection can sequence in either hypochlorhydria or hyperchlorhydria,[19] and therefore ascertain the type of peptic ulcer formed.[20, 21]

NSAIDs induced ulcer: There are two principal mechanisms by which NSAIDs precedent injury to the duodenal and gastric mucosa. On one hand, these medications behave as weak non-ionized acids, that can access into the mucus subcaste simply, and inside the epithelial cells. Distinctive and consummate necessary consequence is the capability of cyclooxygenase

inhibitory enzyme, thereby de-escalating the intracellular concentration of prostaglandins. These play a significant role in maintaining the integrity of the gastroduodenal mucosa function, because of its intramucosal vasodilator outgrowth maintaining complete the blood inflow and degresively amp the local production of mucus and H3CO3, easing the cell developement and epithelization.[22, 23] NSAIDs are astronomically used for a variety of situations to support to minimize pain and inflammation; still, multiple druggies advance GI side effects. NSAIDs responsible for over 90% of all ulcers and roughly 25% of NSAID users will advance PUD.[24] Aspirin duggies are also doubly as likely to advance peptic ulcers as the general population.[25] Distinctive advance a milder position of topical damage, which is seen as mucosal hemorrhages and attritions and are appretained to as NSAID are responsible for the conversion of applicable perfusion to the gastric mucosa, icing the delivery of O2 and nutrients, as well as take-off poisonous metabolites, opreventing damages to the tissue.[15]

Peptic Ulcer Disease Symptoms

- Mid-epigastric pain
- Eating or burning, nonradiating, reoccurring, episodic pain
- Pain is generally execerabated by food or antacids Gastric ulcer
- Mid-epigastric pain
- Pain is typically aggravated by food and relieved by
- Indigestion
- Epigastric wholeness
- Nausea and vomiting
- Loss of appetite
- Heartburn Alarm symptoms
- Symptom onset after 55 times of age
- Progressive dysphagia
- Persistent of intermittent vomiting
- Severe abdominal pain
- Weight loss and/or anorexia
- Family history of gastric malignancy
- Blood in stool, melena, hematemesis, and/or anemia

Note. Nonsteroidal anti-inflammatory drug-induced ulcers are frequently silent with perforation or bleeding as initial presentation. Adapted from "Peptic Ulcer Disease," by F. Akhtar, P. Shelton, and A. Dinh, 2019, In F. Domino, R. Baldor, J. Golding., & M. Stephens (Eds.), The 5-Minute Clinical Consult (27th ed., pp. 748–749), Philadelphia, PA: Wolters Kluwer.



Types Of Peptic Ulcer

Duodenal ulcer: Most common peptic ulcer generally located in the proximal duodenum Multiple ulcers and/or ulcers distal to the alternate portion of the duodenum raise clinical dubitations of gastrinoma (Zollinger–Ellison syndrome).

Gastric ulcer: Lower common than duodenal ulcer in the absence of NSAID operating generally located along the lower curve of the antrum.

Esophageal ulcers: Located in the distal esophagus; generally secondary to gastroesophageal reflux disease Seen also with gastrinoma.

Ectopic gastric mucosal ulceration: Can develop with Meckel diverticulum.

TREARTMENT OF PEPTIC ULCER

Several conventional treatments, similar as PPIs, H2 receptor antagonists, potassium competitive acid blockers, antacids, and antibiotics, have been proved for the treatment of cases presented with peptic ulcers.[26,27] The PPIs have been proved to block the gastric hydrogen potassium(H+/K+)ATPase, an enzyme that resides on the luminal face of the parietal cell membrane. The ulcer then heals as a result of the reduction in gastric filing vexation and the inhibition of gastric acid out put in the stomach and intestine.[28] Unexpectedly, PPIs have also been reported to treat H. pylori infection when used along with antibiotics. In addition, PPIs have also been used to help ulcers in the cases exposed to long-term use of NSAIDs.[29] The main PPIs are omeprazole, lansoprazole, rabeprazole, esomeprazole and pantoprazole. H2 receptor antagonists, which include

cimetidine, famotidine, ranitidine, and nizatidine, are a different class of medications that are constantly used to treat peptic ulcers.[30] It is known that the histamine type-2 receptors on the basolateral face of stomach parietal cells bind to H2 receptor antagonists. This in turn inhibits the binding and exertion of histamine, thereby snooping with the gastric acid production pathway, ultimately leading to the inhibition of gastric acid stashing.[31] This inhibition of gastric acid stashing further reduces irritation to the gastric lining, eventually helping in themending of an ulcer. Antacids like aluminum hydroxide, sodium bicarbonate, magnesiumhydroxid and calciumcarbonate have been known to act by negativing the gastric acid in the stomach and intestine.[32] Antacids have been known to increase the pH inside gastric and intestinal cells, thereby reducing the acid delivery to these sites. In addition, the antacids have been shown to restrain pepsin, a proteolytic enzyme inside gastric and intestinal cells, therefore producing potent therapeutic effects.[33] Another class of medicines that have a place in conventional remedy for the treatment of peptic ulcer is potassium-competitive acid blockers like vonoprazan and revaprazan.[34] These new medications have been discovered to reversibly bind to K+ ions, inhibit H+/K+ ATPase enzyme ingastric parietal cells, and eventually halt the generation of stomach acid.[35] In addition, this class of medicines possesses cure-dependent goods on gastric acid production, and is known to comprise of fast onset of action[36] Antibiotics like amoxicillin, clarithromycin, metronidazole, tinidazole and levofloxacin have been specificed used to annihilate H. pylori from the digestive tract. This has been seen that two antibiotics are specified to the cases presented with pepticulcer because this has been well reported that combination treatment works more in the case of antibiotics when compared to monotherapy.[37] The correct choice of combination of antibiotics effectively kills H.pylori, which is regarded as a major source of numerous pepticulcers. The antibiotic combination eradicates the bacteria, reduces gastric acid, and eventually leads to the protection of the gastric filing.

Abbreviations: ASA: Acetylsalicylic acid; COX: Cyclooxygenase; H2RAs: Histamine type 2 receptor antagonists; H3CO3: Bicarbonate; Hp: Helicobacter pylori (Hp) NSAIDs: Nonsteroidal anti-inflammatory drugs; Pgs: Prostaglandins; PCN: Penicillin; PPIs: Proton pump inhibitors; PUD: Peptic ulcer disease.

REFRENCES

1. Guerra-Valle M, Orellana-Palma P, Petzold G. Plant-Based Polyphenols:Anti-Helicobacter pylori Effect and Improvement of Gut Microbiota. Antioxidants., 2022 Jan; 11(1): 109.[CrossRef] [PubMed]
2. Ashwin K, Pattanaik AK, Howarth GS. Polyphenolic bioactives as an emerging group of nutraceuticals for promotion of gut health: A review. FoodBioscience, 2021 Dec 1; 44: 101376 [CrossRef]
3. Havlik J, Marinello V, GardyneA, Hou M, Mullen W, Morrison DJ, Preston T, Combet E, Edwards CA. Dietary fibres differentially impact on the production of phenolic acids from rutin in an in vitro fermentation model of the human gut microbiota. Nutrients, 2020 Jun; 12(6): 1577[CrossRef]
4. Søreide, K.; Thorsen, K.; Harrison, E.M.; Bingener, J.; Møller, M.H.; Ohene-Yeboah, M.; Søreide, J.A. Perforated peptic ulcer. Lancet, 2015; 386: 1288–1298. [CrossRef]
5. Zhang, B.B.; Li, Y.; Liu, X.Q.; Wang, P.J.; Yang, B.; Bian, D.L. Association between vacA genotypes and the risk of duodenal ulcer: A meta-analysis. Mol. Biol. Rep., 2014; 41: 7241–7254. [CrossRef] [PubMed]
6. Datta De, D.; Roychoudhury, S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World J. Gastroenterol., 2015; 21: 2883–2895. [CrossRef]
7. Siddique, O.; Ovalle, A.; Siddique, A.S.; Moss, S.F. Helicobacter pylori infection: An update for the internist in the age of increasing global antibiotic resistance. Am. J. Med., 2018; 131: 473–479. [CrossRef] [PubMed]
8. Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y.; et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology, 2017; 153: 420–429. [CrossRef] [PubMed]
9. Zaki, M.; Coudron, P.E.; McCuen, R.W.; Harrington, L.; Chu, S.; Schubert, M.L. H. Pylori acutely inhibits gastric stashing by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine stashing. Am. J. Physiol. Gastrointest. Liver Physiol., 2013; 304: G715–G722. [CrossRef] [PubMed]
10. El-Omar, E.M.; Oien, K.; El-Nujumi, A.; Gillen, D.; Wirz, A.; Dahill, S.; Williams, C.; Ardill, J.E.; McColl, K.E. Helicobacter pylori infection and chronic gastric acid hypostashing. Gastroenterology, 1997; 113: 15–24. [CrossRef]
11. Moss, S.F.; Legon, S.; Bishop, A.E.; Polak, J.M.; Calam, J. Effect of helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet, 1992; 340: 930–932.[CrossRef]
12. Bhala, N.; Emberson, J.; Merhi, A.; Abramson, S.; Arber, N.; Baron, J.A.; Bombardier, C.; Cannon, C.; Farkouh, M.E.; FitzGerald, G.A.; et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet, 2013; 382: 769–779.[CrossRef]
13. Tsimogiannis D, Oreopoulou V. Classification of phenolic compounds in plants. InPolyphenols in plants, 2019 Jan 1; 263-284. AcademicPress.

14. Aravind SM, Wichienchot S, Tsao R, RamakrishnanS, ChakkaravarthiS.Roleofdietary polyphenols on gut microbiota, their metabolites and health benefits. Food Research International., 2021 Apr 1; 142: 110189.[CrossRef]
15. Reis A, Rocha S, deFreitasV. Going "Green" inthe prevention and management of atherothrombotic diseases: The role of dietary polyphenols. Journal of clinicalmedicine., 2021 Jan; 10(7): 1490.[CrossRef]
16. Annunziata G, Sureda A, Orhan IE, Battino M, Arnone A, Jimenez-Garcia M, Capo X, Cabot J, Sanadgol N, Giampieri F, Tenore GC. The neuroprotectiveeffectsofpolyphenols, theirrolein innate immunity and the interplay with the microbiota. Neuroscience & Biobehavioral Reviews., 2021 Sep1; 128: 437-53.[CrossRef]
17. PrabhuS, MolathA, ChoksiH, KumarS, MehraR. Classifications of polyphenols and their potential application in human health and diseases. Int. J. Physiol. Nutr. Phys. Educ., 2021; 6: 293-301. [CrossRef]
18. Huang R, XuC. Anoverview of the perception and mitigation of astringency associated with phenolic compounds. Comprehensive Reviews in Food Scienceand FoodSafety., 2021Jan; 20(1): 1036-74. .[CrossRef]
19. Guerra-ValleM, Lillo-PerezS, PetzoldG, Orellana-Palma P. Effect of freeze crystallization on quality properties of two endemic Patagonian berries juices: Murta (Ugni molinae) and arrayan (Luma apiculata). Foods., 2021 Feb; 10(2): 466. [CrossRef]
20. Orellana-Palma P, Tobar-Bolaños G, Casas-Forero N, Zúñiga RN, Petzold G. Quality attributes of cryoconcentrated calafate (Berberis microphylla) juice during refrigerated storage. Foods, 2020 Sep; 9(9): 1314. [CrossRef]
21. Rodríguez-Daza MC, Pulido-Mateos EC, Lupien-Meilleur J, Guyonnet D, Desjardins Y, Roy D. Polyphenol-mediated gut microbiota modulation: Toward prebiotics and further. Frontiers in Nutrition., 2021; 8. [CrossRef]
22. Moorthy M, Sundralingam U, Palanisamy UD. Polyphenols as prebiotics in the management of high-fat diet-induced obesity:A systematic review ofanimalstudies. Foods., 2021 Feb; 10(2): 299. [CrossRef]
23. Song MY, LeeDY, KimEH. Anti-inflammatoryand anti-oxidative effect of Korean propolis on Helicobacter pylori-induced gastric damage in vitro. Journal of Microbiology, 2020 Oct; 58(10): 878-85.[CrossRef]
24. Khan H, Ullah H, Castilho PC, Gomila AS, D'OnofrioG, FilosaR, WangF, NabaviSM, Daglia M, Silva AS, Rengasamy KR. Targeting NF-κB signalingpathwayincancerbydietarypolyphenols. Critical Reviews in Food Science and Nutrition, 2020 Sep 7; 60(16): 2790-800. [CrossRef]
25. Efenberger-Szmechtyk M, Nowak A, Czyzowska A. Plant extracts rich in polyphenols:Antibacterial agents and natural preservatives for meat and meat products. Critical reviews in food science and nutrition, 2021 Jan 2; 61(1): 149-78. [CrossRef]
26. Holle. Pathophysiology and modern treatment of ulcer disease (Review).IntJMolMed., 2010; 25(4). http://doi.org/10.3892/ijmm_00000368
27. DunlapJJ, Patterson S. Peptic ulcer disease. Gastroenterol Nurs., 2019; 42(5): 451–454. http://doi.org/10.1097/SGA.0000000000000478
28. Khan MA, Howden CW. The role of proton pump inhibitors in the management of upper gastrointestinal disorders. GastroenterolHepatol., 2018; 14(3): 169–175. https://pubmed.ncbi.nlm.nih.gov/29928161/
29. Dharmarajan TS. The use and misuse of proton pump inhibitors: an opportunity for deprescribing. J Am Med Dirs Assoc., 2021; 22(1): 15–22. Availableat: http://doi.org/10.1016/j.jamda.2020.09.046
30. Shim YK, Kim N. The effect of H2receptor antagonist in acid inhibition and its clinical efficacy. Korean J Gastroenterol., 2017; 70(1): 4. http://doi.org/10.4166/kjg.2017.70.1.4
31. El-Dakroury WA, Zewail MB, Elsabahy M, Shabana ME, Asaad GF.Famotidine-loadedsolidself-nanoemulsifyingdrugdelivery system demonstrates exceptional efficiency in amelioration of pepticulcer. IntJPharm., 2022; 611: 121303. http://doi.org/10.1016/j.ijpharm.2021.121303
32. Kim B-W. Diagnosis and treatment of peptic ulcer disease: present and future perspective. Korean J Gastroenterol., 2016; 67(6): 318. Available at: http://doi.org/10.4166/kjg.2016.67.6.318
33. Ansari D, Torén W, Lindberg S, Pyrhönen H-S, Andersson R. Diagnosis and management of duodenal perforations: a narrative review. Scand J Gastroenterol., 2019; 54(8): 939–944. http://doi.org/10.1080/00365521.2019.1647456
34. AnderssonK, CarlssonE.Potassium-competitive acidblockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther, 2005; 108(3): 294–307. http://doi.org/10.1016/j.pharmthera.2005.05.005
35. Cho YK, Choi M-G, Choi SC, et al. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazoleinthetreatmentofgastriculcer. Aliment Pharmacol Ther., 2020; 52(5): 789–797. http://doi.org/10.1111/apt.15865
36. Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol., 2022; 28(28): 3608–3619. http://doi.org/10.3748/wjg.v28.i28.3608
37. Vu TB, Tran TNQ, Tran TQA, Vu DL, Hoang VT. Antibiotic resistance of helicobacter pylori in cases with peptic ulcer. Medicina (Mex), 2022; 59(1): 6. http://doi.org/10.3390/medicina59010006.